Skip to content

An Experiment Comparing Public Reactions to the Labels Community Immunity Versus Herd Immunity.

Community Immunity Versus Herd Immunity

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07102472
Enrollment
350
Registered
2025-08-03
Start date
2025-07-22
Completion date
2025-08-31
Last updated
2025-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attitudes

Brief summary

Participants are shown a scenario consisting of static images from a previous study (herdimm) showing a visualization of how herd immunity works. Participants are randomized to see the text with the term herd immunity or community immunity.

Interventions

BEHAVIORALUsing the term community immunity instead of herd immunity

In the intervention arm, participants are shown the less traditional term community immunity in place of the more traditional herd immunity

BEHAVIORALHerd immunity

Using the traditional term herd immunity

Sponsors

Laval University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Able to use a computer * Able to use the internet * Able to read and respond to questions in English or French * 18+ years old and living in Canada

Exclusion criteria

\- Unable to view images on a computer

Design outcomes

Primary

MeasureTime frameDescription
Orientation towards protection of othersImmediately after the interventionA measure of the extent to which people believe that individual vaccination behavior is important to protect others. Question wording: When a safe and effective vaccine exists that can prevent people from catching and passing on a contagious disease, it is important for people to get vaccinated to protect ... Measured across two to three items (family, others in the community, people who are more vulnerable to disease) on a 7-point Likert-type scale (strongly disagree = 1, strongly agree = 7).

Contacts

Primary ContactHolly Witteman, PhD
holly.witteman@fmed.ulaval.ca418-656-2131

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026